Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)

Inclusion Criteria: * Recipients of a first liver allograft from a deceased donor * Transplanted for less than four weeks at enrolment. * Without inter-current progressive life-threatening or graft-threatening disease. * Having signed a written informed consent for their participation in the study. * Affiliated to, or beneficiary of, a social security regimen Exclusion Criteria: * Recipients of a split-liver transplantation. * Recipients of any transplanted organ other than the liver * Patient who has undergone colon resection * Patients under legal protection (guardianship, curatorship). * Patient presenting any contra-indication to tacrolimus or to MMF according to the summary of product characteristics (SmPC) of ENVARSUS®, ADVAGRAF® and CELLCEPT®. * Patients in whom everolimus-based calcineurin inhibitors (CNI) minimization is anticipated * Patients treated with HIV or HCV protease inhibitors. * Pregnant or lactating women. * Women of childbearing potential without any effective contraceptive method (according to the guidelines of CTFG, Clinical Trial Facilitation Group, related to contraception and pregnancy test in clinical trials) or not practicing sexual abstinence. * Sexually active men having a female partner, without any effective contraception. * Patients incapable of understanding the purposes and risks of the study, who cannot give written informed consent, or who are unwilling to comply with the study protocol. * Patients enrolled in another clinical study evaluating drugs or therapeutic strategies potentially interfering with the objectives of the EASY study.